Group One Trading, L.P. Unity Biotechnology, Inc. Transaction History

Group One Trading, L.P.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 09, 2022	SELL	$0.4 - $4.27 $14,431 - $154,057	-36,079 Reduced 78.84%	9,685 $4,000
Q2 2022 Aug 11, 2022	SELL	$0.56 - $1.29 $3,416 - $7,869	-6,100 Reduced 11.76%	45,764 $26,000
Q1 2022 May 12, 2022	BUY	$0.72 - $1.86 $11,342 - $29,300	15,753 Added 43.62%	51,864 $58,000
Q4 2021 Feb 11, 2022	BUY	$1.3 - $3.17 $43,903 - $107,057	33,772 Added 1443.86%	36,111 $53,000
Q3 2021 Nov 12, 2021	SELL	$2.91 - $4.5 $7,225 - $11,173	-2,483 Reduced 51.49%	2,339 $7,000
Q2 2021 Aug 10, 2021	BUY	$4.15 - $6.3 $20,011 - $30,378	4,822 New	4,822 $22,000
Q4 2020 Feb 10, 2021	SELL	$3.42 - $6.36 $186,171 - $346,212	-54,436 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$2.94 - $12.43 $159,483 - $674,277	54,246 Added 28550.53%	54,436 $188,000
Q2 2020 Aug 13, 2020	BUY	$5.28 - $9.67 $1,003 - $1,837	190 New	190 $2,000
Q3 2019 Nov 12, 2019	SELL	$5.62 - $9.63 $6,182 - $10,593	-1,100 Closed	0 $0
Q2 2019 Aug 09, 2019	BUY	$7.59 - $10.21 $759 - $1,021	100 Added 10.0%	1,100 $10,000
Q1 2019 May 13, 2019	BUY	$7.65 - $16.66 $7,650 - $16,660	1,000 New	1,000 $8,000

4.41M

Ticker UBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,036,200
Market Cap $14M
Description
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular d...

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

Stay updated on Group One Trading, L.P. with notifications on news.